51467-70-0

Basic information

• Product Name: 2,4,6-Trimethylpyridin-3-amine
• Synonyms: 2,4,6-TRIMETHYLPYRIDIN-3-AMINE;2.4.6-TRIMETHYL-3-AMINOPYRIDINE;3-pyridinamine, 2,4,6-trimethyl-;(2,4,6-trimethyl-3-pyridyl)amine;2,4,6-trimethyl-pyridin-3-ylamine;2,4,6-trimethylpyridin-3-amine(SALTDATA: FREE);3-aMino-2,4,6-triMethylpyridine
• CAS NO: 51467-70-0
• Molecular Formula: C₈H₁₂N₂
• Molecular Weight: 136.19
• Mol File: 51467-70-0.mol

Chemical Properties

• Melting Point: 66 °C
• Boiling Point: 256.4 °C at 760 mmHg
• Flash Point: 132.6 °C
• Appearance: /
• Density: 1.018 g/cm³
• PKA: 8.26±0.18(Predicted)
• CAS DataBase Reference: 2,4,6-Trimethylpyridin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-Trimethylpyridin-3-amine(51467-70-0)
• EPA Substance Registry System: 2,4,6-Trimethylpyridin-3-amine(51467-70-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 51467-70-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2,4,6-Trimethylpyridin-3-amine is used as a chemical intermediate for the synthesis of various compounds. Its amine groups facilitate its involvement in a wide range of chemical reactions, making it a valuable component in the production of different chemical products.
Used in Research Applications:
2,4,6-Trimethylpyridin-3-amine is used as a research compound for studying its properties and potential applications in various fields. Its unique structure and reactivity provide opportunities for exploration in chemical research and development.
Used in Pharmaceutical Industry:
2,4,6-Trimethylpyridin-3-amine is used as a building block in the development of new pharmaceutical compounds. Its amine groups can be modified to create derivatives with potential therapeutic applications, contributing to the advancement of drug discovery and innovation.
Used in Material Science:
2,4,6-Trimethylpyridin-3-amine is used as a component in the development of new materials with specific properties. Its chemical structure can be incorporated into the design of materials with tailored characteristics, such as improved stability or enhanced reactivity, for use in various industries.

InChI:InChI=1/C8H12N2/c1-5-4-6(2)10-7(3)8(5)9/h4H,9H2,1-3H3

Upstream product

• 21203-55-4 2,4,6-trimethyl-3-nitro-pyridine 
• 108-75-8 2,4,6-trimethyl-pyridine 

Downstream Products

• 101289-51-4 N-(4-acetoxy-2,4,6-trimethyl-4H-[3]pyridylidene)-benzenesulfonamide 
• 34456-56-9 N-(2,4,6-trimethyl-pyridin-3-yl)-benzenesulfonamide 
• 111526-27-3 N-(2,4,6-trimethyl-1-oxy-[3]pyridyl)-benzenesulfonamide 
• 101588-17-4 N-benzenesulfonyl-N-(2,4,6-trimethyl-[3]pyridyl)-glycine-methyl ester 
• 101289-54-7 N-benzenesulfonyl-N-(2,4,6-trimethyl-[3]pyridyl)-glycine 
• 112991-26-1 bis-benzenesulfonyl-(2,4,6-trimethyl-1-oxy-[3]pyridyl)-amine 

Relevant articles and documents

Microwave-assisted reduction of aromatic nitro compounds with novel oxo-rhenium complexes

The reduction of several aromatic nitro compounds to amines by means of the two novel catalytic systems ([IMes]2ReOBr3)/PhSiH3 and ([Py]3ReNOBr2)/PhSiH3 under microwave irradiation is here reported. These two systems were able to perform the reduction of nitro groups with higher TON and TOF when compared with previously reported systems based on oxo-rhenium core under standard heating, although they showed a lesser broad reaction scope compared with the known systems.

1N-alkyl-N-arylpyrimidinamines and derivatives thereof

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R4, R5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines

The synthesis and CRF receptor binding affinities of several new series of N-aryltriazolo- and -imidazopyrimidines and -pyridines are described. These cyclized systems were prepared from appropriately substituted diaminopyrimidines or -pyridines by nitrous acid, orthoester, or acyl halide treatment. Variations of amino (ether) pendants and aromatic substituents have defined the structure-activity relationships of these series and resulted in the identification of a variety of high-affinity agents (K(i)'s 1 has been selected for further pharmacological studies that will be reported in due course.

Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists

A series of purin-8-ones was prepared and discovered to have excellent binding affinity to the CRH-R1 receptor. Structure-activity studies focused on amine side-chain optimization, urea substitution and pyridyl isostere incorporation. Thus, the highly potent purin-8-ones show promise as a new class of potential anxiolytics and/or antidepressants.